{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T04:24:36Z","timestamp":1773548676430,"version":"3.50.1"},"reference-count":120,"publisher":"Elsevier","isbn-type":[{"value":"9780443136535","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001509","name":"Royal Society Te Ap\u0101rangi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020950","name":"Department of Pathology, Northwestern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.ircmb.2023.06.002","type":"book-chapter","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T08:29:10Z","timestamp":1688718550000},"page":"41-66","source":"Crossref","is-referenced-by-count":5,"title":["Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the 68 Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: Subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib5","doi-asserted-by":"crossref","unstructured":"Aggarwal, R. R., Aparicio, A., Heidenreich, A., Sandhu, S. K., Zhang, Y., Salvati, M., \u2026 Hashemi Sadraei, N. (2021). Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). Wolters Kluwer Health.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5100"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancerplatinum chemotherapy for variant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2003.02.083","article-title":"Biology of prostate-specific antigen","volume":"21","author":"Balk","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.trecan.2021.11.008","article-title":"Epigenetic basis and targeting of cancer metastasis","volume":"8","author":"Banerjee","year":"2022","journal-title":"Trends in Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/1078-0432.CCR-15-0137","article-title":"The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancerCTCs in neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.177","article-title":"Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC)","volume":"32","author":"Beltran","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: Efficacy and biomarkersalisertib for neuroendocrine prostate cancer","volume":"25","author":"Beltran","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancervariants of prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3762","article-title":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","volume":"28","author":"Berchuck","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib19","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1038\/s41388-020-01493-8","article-title":"MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer","volume":"39","author":"Bhagirath","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","article-title":"A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","volume":"25","author":"Brown","year":"2022","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib22","doi-asserted-by":"crossref","unstructured":"Chatterjee, A., Rodger, E. J., Eccles, M. R. (2018). Epigenetic drivers of tumourigenesis and cancer metastasis.\u00a0Seminars in Cancer Biology, 51, 149\u2013159.","DOI":"10.1016\/j.semcancer.2017.08.004"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.18632\/oncotarget.14042","article-title":"Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis","volume":"8","author":"Chatterjee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/ERC-11-0368","article-title":"Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway","volume":"19","author":"Chen","year":"2012","journal-title":"Endocrine Related Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"eaam6826","DOI":"10.1126\/scisignal.aam6826","article-title":"Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer","volume":"10","author":"Chen","year":"2017","journal-title":"Science Signaling"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib26","doi-asserted-by":"crossref","first-page":"IJE20","DOI":"10.2217\/ije-2019-0008","article-title":"Treatment-emergent neuroendocrine prostate cancer: Molecularly driven clinical guidelines","volume":"6","author":"Clermont","year":"2019","journal-title":"International Journal of Endocrine Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41698-021-00211-1","article-title":"Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis","volume":"5","author":"Conteduca","year":"2021","journal-title":"npj Precision Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"v349","DOI":"10.1093\/annonc\/mdz248.045","article-title":"Circulating tumour cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis","volume":"30","author":"Conteduca","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib30","first-page":"626","article-title":"The role of LHRH antagonists in the treatment of prostate cancer","volume":"23","author":"Crawford","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10555-013-9455-3","article-title":"The non-coding transcriptome as a dynamic regulator of cancer metastasis","volume":"33","author":"Crea","year":"2014","journal-title":"Cancer and Metastasis Reviews"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib32","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/epi.16.6","article-title":"The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer","volume":"8","author":"Crea","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2012.00048","article-title":"Management of biochemical recurrence after primary localized therapy for prostate cancer","volume":"2","author":"Darwish","year":"2012","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib35","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/ERC-19-0420","article-title":"The epigenetic and transcriptional landscape of neuroendocrine prostate cancer","volume":"27","author":"Davies","year":"2020","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nature Reviews Urology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib37","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"De Bono","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib38","doi-asserted-by":"crossref","unstructured":"Dupont, C., Armant, D. R., Brenner, C. A. (2009). Epigenetics: Definition, mechanisms and clinical perspective. Seminars in Reproductive Medicine, 27, 351\u2013357.","DOI":"10.1055\/s-0029-1237423"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clinical Nuclear Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib41","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41467-020-15426-2","article-title":"Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model","volume":"11","author":"Faugeroux","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib42","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3389\/fonc.2019.00858","article-title":"Androgen receptor signaling in the development of castration-resistant prostate cancer","volume":"9","author":"Feng","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108585","article-title":"Post-transcriptional gene regulation by MicroRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer","volume":"34","author":"Fernandes","year":"2021","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1464-410X.1995.tb07232.x","article-title":"Magnetic resonance imaging for the diagnosis of prostate cancer metastatic to bone","volume":"75","author":"Fujii","year":"1995","journal-title":"British Journal of Urology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanomapersonalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib47","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib48","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1038\/ncomms8620","article-title":"PTEN regulates DNA replication progression and stalled fork recovery","volume":"6","author":"He","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib49","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: Small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib51","first-page":"6063","article-title":"Molecular and cellular mechanisms of castration resistant prostate cancer","volume":"15","author":"Huang","year":"2018","journal-title":"Oncology letters"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41391-017-0017-6","article-title":"Platinum sensitivity in metastatic prostate cancer: Does histology matter?","volume":"21","author":"Humeniuk","year":"2018","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e16532","article-title":"Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer","volume":"35","author":"Humeniuk","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153731","article-title":"Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies","volume":"229","author":"Ida","year":"2022","journal-title":"Pathology-Research and Practice"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib55","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.21873\/anticanres.15699","article-title":"Treatment outcomes in neuroendocrine prostate cancer","volume":"42","author":"Iwamoto","year":"2022","journal-title":"Anticancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib56","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.4_suppl.204","article-title":"Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC)","volume":"32","author":"Kaur","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203820119","article-title":"Delta-like ligand 3\u2013targeted radioimmunotherapy for neuroendocrine prostate cancer","volume":"119","author":"Korsen","year":"2022","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/JTO.0b013e31823c5c16","article-title":"Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches","volume":"7","author":"Krebs","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib61","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.3390\/ijms21186658","article-title":"Dual effects of non-coding RNAs (ncRNAs) in Cancer stem cell biology","volume":"21","author":"Kyriazi","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib62","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib63","first-page":"1","article-title":"LHRH agonists for the treatment of prostate cancer: 2012","volume":"14","author":"Lepor","year":"2012","journal-title":"Reviews in Urology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib64","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.7150\/thno.23180","article-title":"Genes involved in prostate cancer progression determine MRI visibility","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib65","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/modpathol.2011.7","article-title":"ERG gene rearrangements are common in prostatic small cell carcinomas","volume":"24","author":"Lotan","year":"2011","journal-title":"Modern Pathology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib66","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41467-019-09784-9","article-title":"LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling","volume":"10","author":"Luo","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c1928","article-title":"Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: Continuous survey","volume":"340","author":"Lyratzopoulos","year":"2010","journal-title":"BMJ (Clinical Research ed.)"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A phase I\/II study of rovalpituzumab tesirine in delta-like 3\u2014Expressing advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ precision oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fgene.2015.00090","article-title":"DNA methyltransferase 1 mutations and mitochondrial pathology: Is mtDNA methylated?","volume":"6","author":"Maresca","year":"2015","journal-title":"Frontiers in Genetics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib71","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1111\/bju.13631","article-title":"Phenotypic diversity of circulating tumour cells in patients with metastatic castration\u2010resistant prostate cancer","volume":"120","author":"McDaniel","year":"2017","journal-title":"BJU International"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1756287217738985","article-title":"Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: Perspectives across the spectrum of care","volume":"10","author":"Meani","year":"2018","journal-title":"Therapeutic Advances in Urology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02255-y","article-title":"Aggressive variants of prostate cancer: Underlying mechanisms of neuroendocrine transdifferentiation","volume":"41","author":"Merkens","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib74","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00330-011-2173-8","article-title":"Assessing response in bone metastases in prostate cancer with diffusion weighted MRI","volume":"21","author":"Messiou","year":"2011","journal-title":"European Radiology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","article-title":"Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model","volume":"4","author":"Meuwissen","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2021.03.023","article-title":"Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells","volume":"150","author":"Mout","year":"2021","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib78","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/RLU.0000000000000849","article-title":"18F-fluciclovine PET\/CT for the detection of prostate cancer relapse: A comparison to 11C-choline PET\/CT","volume":"40","author":"Nanni","year":"2015","journal-title":"Clinical Nuclear Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib79","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib80","doi-asserted-by":"crossref","unstructured":"Panebianco, V., Barchetti, F., Sciarra, A., Ciardi, A., Indino, E. L., Papalia, R., \u2026 Catalano, C. (2015). Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized study.\u00a0Urologic Oncology, 33, 1\u201317.e7.","DOI":"10.1016\/j.urolonc.2014.09.013"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-85812-3","article-title":"Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer","volume":"11","author":"Peter","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib82","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient derived organoids to model rare prostate cancer phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5029","article-title":"Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC)","volume":"35","author":"Puca","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib84","doi-asserted-by":"crossref","first-page":"giy050","DOI":"10.1093\/gigascience\/giy050","article-title":"The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications","volume":"7","author":"Ramnarine","year":"2018","journal-title":"GigaScience"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World Journal of Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib86","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nm.4341","article-title":"Biology and evolution of poorly differentiated neuroendocrine tumors","volume":"23","author":"Rickman","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib87","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach Iii","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-019-0710-5","article-title":"Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types","volume":"11","author":"Rodger","year":"2019","journal-title":"Clinical Epigenetics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib89","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib91","series-title":"Prostate biopsy interpretation: An illustrated guide","author":"Shah","year":"2019"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib92","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41420-019-0218-y","article-title":"Targeting Wnt\/EZH2\/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer","volume":"5","author":"Shan","year":"2019","journal-title":"Cell Death Discovery"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib93","doi-asserted-by":"crossref","first-page":"E6544","DOI":"10.1073\/pnas.1518007112","article-title":"A basal stem cell signature identifies aggressive prostate cancer phenotypes","volume":"112","author":"Smith","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib94","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.trecan.2020.02.007","article-title":"Promoter DNA hypermethylation and paradoxical gene activation","volume":"6","author":"Smith","year":"2020","journal-title":"Trends in Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib95","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: A strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.25259\/JCIS_139_2019","article-title":"Axumin positron emission tomography: Novel agent for prostate cancer biochemical recurrence","volume":"9","author":"Songmen","year":"2019","journal-title":"Journal of Clinical Imaging Science"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib97","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000444087","article-title":"Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: Clinical outcomes and preliminary correlation with biological factors","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib98","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib99","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.21873\/anticanres.14340","article-title":"Clinical features of treatment-related neuroendocrine prostate cancer: A case series","volume":"40","author":"Suzuki","year":"2020","journal-title":"Anticancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib100","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.3390\/cancers13225765","article-title":"Imaging of neuroendocrine prostatic carcinoma","volume":"13","author":"Taher","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib101","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib102","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib103","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.juro.2007.03.003","article-title":"Guideline for the management of clinically localized prostate cancer: 2007 update","volume":"177","author":"Thompson","year":"2007","journal-title":"The Journal of Urology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib105","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: The European Association of Urology prostate cancer guidelines panel recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"European urology focus"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib107","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1541-7786.MCR-19-1245","article-title":"Targeting RET kinase in neuroendocrine prostate cancer","volume":"18","author":"VanDeusen","year":"2020","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib108","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3390\/cancers14143446","article-title":"Assessment of a size-based method for enriching circulating tumour cells in colorectal cancer","volume":"14","author":"Vasantharajan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188514","article-title":"The epigenetic landscape of circulating tumour cells","volume":"1875","author":"Vasantharajan","year":"2021","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Current Oncology Reports"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib111","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: Factors associated with time to development of NEPC and survival from NEPC diagnosis\u2014A systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib112","first-page":"93","article-title":"Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm","author":"Wang","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib113","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality-the future of PSA screening","volume":"382","author":"Welch","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib114","first-page":"109","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","author":"Wyatt","year":"2017","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib115","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cas.12473","article-title":"Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system","volume":"105","author":"Yamaguchi","year":"2014","journal-title":"Cancer Science"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib116","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1038\/s41467-018-06177-2","article-title":"Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers","volume":"9","author":"Zhang","year":"2018","journal-title":"Nature communications"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib117","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib118","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161858","article-title":"A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer","volume":"132","author":"Zhao","year":"2022","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib119","first-page":"2856","article-title":"Effect of PTEN loss on metabolic reprogramming in prostate cancer cells","volume":"17","author":"Zhou","year":"2019","journal-title":"Oncology letters"},{"key":"10.1016\/bs.ircmb.2023.06.002_bib120","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","article-title":"Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Research"}],"container-title":["International Review of Cell and Molecular Biology","Epigenetic Regulation of Cancer - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:33:07Z","timestamp":1762597987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644823000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443136535"],"references-count":120,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2023.06.002","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}